New Product Streamlines Prior Authorization to Improve Patient, Provider, and Payer Outcomes
BOSTON, MA / ACCESS Newswire / May 29, 2025 / 1upHealth, a leader in health data interoperability, today announced the launch of its 1up Prior Authorization solution. The solution is designed to ensure compliance with the CMS Interoperability and Prior Authorization final rule (CMS-0057) while delivering measurable ROI through reduced provider burden and lower administrative costs for payers. To accelerate adoption of electronic Prior Authorization (ePA), 1upHealth is also building strategic partnerships with Utilization Management (UM) and Prior Authorization (PA) policy vendors. These partnerships aim to simplify integration and speed up deployment for payer customers.
While PA programs are intended to manage costs, current processes are largely manual and create significant burdens across the healthcare system. For providers, this burden translates to less time spent on patient care; for payers, it drives up administrative costs and hinders member experience. According to the American Medical Association, 29% of physicians reported that PA led to serious adverse events for patients, and nearly 90% said it contributes to physician burnout. Separately, CAQH estimates that transitioning to ePA could save the industry at least $515M annually.
The 1up Prior Authorization solution digitizes and streamlines the PA process for health plans by managing complex integrations and providing real-time visibility, flexibility, and control at every stage. Built in accordance with Da Vinci FHIR Implementation Guides, the tool enables connectivity with all major EHRs, PA policy vendors, and utilization management systems. By simplifying prior authorization workflows, 1upHealth’s solution not only ensures regulatory compliance but also delivers measurable improvements for patients, providers, and payers.
“The CMS final rule not only set the stage for healthcare’s long overdue digital transformation, but it provided the kindling needed to solve one of the industry’s biggest pain points: prior authorization,” said Andrew Boyd, CEO of 1upHealth. “With 1upHealth’s latest releases, we’re taking away the complexity of the PA process while going beyond compliance to drive critical outcomes such as: reduced administrative costs and improved efficiency for payers; broader adoption and reduced burden for providers; and, most importantly, improved outcomes and higher satisfaction for patients.”
1upHealth is also building its ecosystem of PA partners, offering a comprehensive end-to-end ePA solution that integrates into a health plan’s existing technology stack. The 1up Prior Authorization solution connects to all industry EHRs, PA policy vendors, and UM vendors. Today, 1upHealth is integrated with EHR vendors Epic and Meditech; UM transformation provider Cohere Health; and prior authorization systems vendor Itiliti Health. Additional technology partners are actively testing and growing the ecosystem.
“Healthcare’s longstanding interoperability issues have made it frustratingly difficult to solve even the most basic challenges, such as ensuring patients receive the right care at the right time,” said Mohammad Jouni, Chief Product and Technology Officer of 1upHealth. “1upHealth is changing that by making it dramatically easier to access and integrate health data. This unlocks critical use cases like electronic prior authorization that not only improve clinical outcomes, but also streamline operations and eliminate the inefficiencies the industry has long accepted as inevitable. This is the foundational infrastructure healthcare has always needed but too often overlooked, and I’m proud that 1upHealth is leading the charge.”
1upHealth will host a webinar on June 4, titled “ePA in Action: Live Demo + Roadmap to CMS-0057 Compliance” to cover the ePA requirements and introduce its new solution. To learn more and register, visit this page.
About 1upHealth
Driven by a purpose of better healthcare for all through better data, 1upHealth is the national leader in health data interoperability and one of the fastest-growing health IT companies in the United States. Our modern data platform is built on a standards-based cloud architecture specifically designed for the healthcare industry, making it easy to acquire, manage, share, and compute data. From leading health plans and state Medicaid agencies to innovative digital health organizations and top-performing ACOs, over 90 health organizations rely on 1upHealth to seamlessly exchange data across the healthcare ecosystem to reduce risk, lower costs, and improve patient outcomes.
ATHENS, GR / ACCESS Newswire / May 29, 2025 / Elvictor Group Inc. (OTC PINK:ELVG) (“Elvictor” or the “Company”), a leader in maritime recruitment and crew management, today announced substantial operational growth across key performance areas in Q1 2025, strengthening its market position and future outlook.
In Q1 2025, Elvictor reported strong financial results, reporting a net profit of $60,230. Revenue increased to $602,368, up from $572,709 in Q1 2024, driven by the Company’s continued focus on operational efficiency and strategic positioning in the maritime crew management sector.
Operationally, Elvictor deployed 3,187 seafarers in Q1 2025, a 41.23% increase compared to the average of the two preceding quarters. The Company’s client roster also expanded to 49 clients, reflecting a robust 32.43% year-over-year increase.
This momentum builds on steady growth achieved throughout 2024, during which onboard seafarer numbers rose from 2,257 in Q1 to 2,570 in Q4 – a 13.9% increase. During the same period, Elvictor’s client base grew from 37 to 43, marking a 16.22% increase.
Looking forward, Elvictor is engaged in active discussions with potential new clients, representing a fleet expansion opportunity of over 100 vessels. Management anticipates onboarding up to 40 additional vessels by year-end 2025. This fleet growth could drive the deployment of an additional 800 seafarers and deliver a material increase in Elvictor’s EBITDA.
Konstantinos S. Galanakis, CEO of Elvictor Group Inc. commented: “Our sustained growth trajectory underscores our commitment to excellence in maritime management and recruitment. As we continue to expand both our onboard workforce and client portfolio, we are confident in our ability to scale efficiently, enhance operational performance, and create long-term value for our stakeholders.”
Elvictor’s strong performance highlights the scalability of its digitalized platform, as well as its longstanding, trusted relationships within the global shipping industry. As the Company pursues further growth in 2025 and beyond, it remains committed to delivering operational excellence, financial transparency, and value-driven client partnerships.
About Elvictor Group, Inc.
Elvictor Group, Inc. (OTC PINK: ELVG) is transforming the fragmented maritime industry through its fully digitalized crew and ship management platform designed to enhance operational efficiency and reduce costs. With a strategic focus on AI-driven workforce solutions, M&A-driven expansion, and cost-efficient vessel ownership, Elvictor is ushering in a new era of transparency in the shipping industry. For more information, visit: https://www.elvictorgroup.com, and follow us on LinkedIn.
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets, and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. The Company does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated status of such statements. Therefore, in no case whatsoever will the Company and its affiliates be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
Next-Gen Conversational Analytics Now Available, Secure, and Fully Embeddable
SAN FRANCISCO, CA / ACCESS Newswire / May 29, 2025 / GoodData today announced the general availability of GoodData AI Assistant, a conversational analytics solution that transforms how business users engage with data. Built to scale, the AI Assistant enables users to ask questions in plain language and receive precise, governed insights right where decisions are made.
As a flagship feature of the GoodData AI platform, the AI Assistant redefines how organizations unlock value from analytics. It blends the power of generative AI with semantic context and robust enterprise controls, making data exploration faster, smarter, and secure by design.
Conversational Analytics at Enterprise Scale
With the release of GoodData AI Assistant, organizations gain access to a conversational interface that brings AI-driven data exploration to every user, without compromising governance or performance. With the launch of AI Assistant, GoodData introduces a suite of intelligent capabilities tailored for business decision-makers and designed with enterprise demands at the fore:
Natural Language Visualization Creation: Users can generate charts or tables simply by describing what they want to see. The assistant interprets the intent, queries the data model, and renders visual insights in seconds.
Autocomplete for Analytics Objects: Query creation becomes faster and more intuitive with predictive suggestions for metrics, attributes, and filters.
Deep Search: Users can discover dashboards and visualizations using semantic search and context – no need to know exact names or locations.
Insight Saving & Permissions: Users can save ad-hoc visualizations directly into the analytics environment, with configurable access controls to maintain oversight and governance.
Next-Step Suggestions: The assistant recommends follow-up actions, helping users refine their analysis and reach insights faster.
Usage Governance: Enforce cost control and responsible AI usage with configurable usage limits and monitoring tools.
White-Labeling: The assistant can be seamlessly embedded and fully rebranded, enabling clients to offer it as part of their own applications without referencing GoodData.
Enterprise-Grade Infrastructure: A high-availability architecture ensures consistent performance, reliability, and scalability for mission-critical deployments.
How It Works: Under the Hood
GoodData AI Assistant is built on a modern, scalable architecture designed for enterprise use:
RAG Architecture: Uses Retrieval-Augmented Generation (RAG) to pull only the most relevant parts of the semantic layer before sending them to the LLM. This improves speed, accuracy, and scalability – even for large models.
Efficient on Large Models: By narrowing the input, the assistant can handle very large semantic layers without compromising performance.
LLM-Agnostic: Compatible with all major LLM providers. No vendor or vector store lock-in (e.g., OpenAI), giving full flexibility.
Validated by AI: Responses are reviewed using an “LLM-as-a-judge” method, where dedicated models assess and validate answers before returning them to the user.
This approach ensures accurate, fast, and secure insights while maintaining full enterprise control.
“GoodData AI Assistant is designed to bridge the gap between technical analytics and accessible decision-making,” said Jan Franek, Senior Product Manager at GoodData. “We’re empowering business users to get reliable insights instantly – while maintaining the control and governance enterprises demand.”
Why It Matters
The AI Assistant drastically reduces time-to-insight, supports business users without deep technical knowledge, and integrates directly into existing workflows through APIs and SDKs. It’s more than a chatbot – it’s a business companion that understands your data and your business context.
Key Benefits
Smarter Exploration: From detailed explanations to guided next steps, users receive contextually relevant insights with ease.
Faster Time to Value: Empower teams with instant answers that align with your data model and business logic.
Secure and Compliant: No data leaves your environment. AI outputs are explainable, auditable, and private by default.
Composable by Design, Ready for Business
Part of the broader GoodData AI ecosystem, the AI Assistant is built on a composable architecture, making it easy to use out of the box or embed seamlessly into custom applications via SDKs and APIs. Powered by the Intelligent Semantic Layer and the AI-ready Analytics Lake, it ensures every insight is accurate, governed, and aligned with your business logic.
Looking Ahead
The launch of the AI Assistant is a key milestone in the broader GoodData AI vision, where every interaction with analytics is intuitive, intelligent, and context-aware. Looking forward, the AI Assistant will become even more proactive, integrated, and adaptive.
As part of the evolving GoodData AI platform, the Assistant will continue to benefit from deeper orchestration across the semantic layer, tighter integration with enterprise workflows, and support for the latest advancements in generative AI, always with full flexibility, governance, and control.
About GoodData
GoodData is the AI-native analytics platform built for speed, scale, and trust, helping companies deliver real-time insights – embedded, branded, and everywhere your users need them.
Founded in 2007, and with offices in both the U.S. and Europe, GoodData serves over 140,000 of the world’s top companies and 3.2 million users, helping them drive meaningful change and maximize the value of their data.
A unique oral drug candidate that is shown to restore vision and regenerate the retina in an animal model, addressing a major unmet need in ocular therapeutics
MIAMI, FLORIDA / ACCESS Newswire / May 29, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), an emerging leader in age-reversal science, today announced compelling preclinical results from a study evaluating its novel oral therapeutic, Telomir-1, in a genetically modified zebrafish model of age-related macular degeneration (AMD). Following a 14-day oral dosing regimen, Telomir-1 reversed central vision response and vision acuity, restored retinal degeneration and architecture, and significantly reduced oxidative stress-achieving improvements across several FDA-recognized surrogate endpoints relevant to AMD.
The study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which combines genetic mutations associated with premature aging (WRN), mitochondrial dysfunction (ND6), and chronic senescence (Sen57). These animals exhibit progressive retinal degeneration, visual impairment, and oxidative stress-closely modeling dry AMD and geographic atrophy in humans.
Model Transformation: From Degeneration to Recovery
Before treatment, the aged (18-month-old) zebrafish demonstrated clear signs of neurodegeneration and visual impairment. Mutant animals showed sluggish, uncoordinated swimming behavior and delayed responses to visual stimuli such as light and movement-evidence of significant vision loss.
Microscopic analysis of their retinas revealed approximately 15% total retinal degeneration, affecting several critical layers:
The inner nuclear layer (INL) was thinned. This layer acts as the retina’s central processing zone, where signals from light-sensitive photoreceptors are refined before being passed deeper into the eye.
The ganglion cell layer (GCL) was degraded. This layer contains neurons that form the optic nerve, which sends visual information to the brain. Damage here disrupts vision at its source.
The inner plexiform layer (IPL) volume was reduced. IPL is a retinal layer located between the inner nuclear layer (INL) and the ganglion cell layer (GCL). It may contribute to disease processes through inner retinal changes, inflammation, or vitreoretinal interactions.
The outer plexiform layer (OPL) showed early deterioration. This layer connects photoreceptors to other retinal cells and is essential for detecting changes in light and contrast.
In addition to retinal damage, the diseased animals exhibited reactive oxygen species (ROS) levels nearly four times higher than healthy controls-indicating intense oxidative stress-and suffered a 15% mortality rate during the two-week study window.
After receiving Telomir-1, treated animals demonstrated marked recovery:
The zebrafish resumed active, coordinated swimming and responded significantly better to light and movement, reflecting restored vision.
Retinal architecture was structurally restored, including:
Full recovery of INL thickness, restoring core signal processing in the retina.
Improved GCL integrity, reactivating the transmission of visual information to the brain.
Significant augmentation of IPL size, indicating improved processing of visual signals
Improvement of OPL structure, maintaining input from photoreceptors.
ROS levels were reduced by up to 50%, and no mortality occurred in any Telomir-1 treatment group.
Histological cross-sections confirmed Telomir-1’s ability to regenerate not only the inner retinal layers, but also additional retinal structures-supporting improved-laminar retinal restoration and function.
Collectively, these results demonstrate Telomir-1’s ability to restore visual function, reverse retinal degeneration, reduce oxidative stress, and improve survival-all from a short oral treatment regimen.
“This breakthrough reinforces our vision at Telomir: to redefine how we treat age-related diseases by going beyond symptom management and targeting the root mechanisms of degeneration,” said Erez Aminov, Chief Executive Officer of Telomir. “To our knowledge, no oral drug has ever demonstrated this level of retinal restoration and vision recovery in any AMD model-this is a meaningful leap forward for patients and the field.”
“The preclinical success achieved in this AMD model is truly remarkable,” added Dr. Angel, Chief Scientific Advisor of Telomir. “Telomir-1 when studied orally, restored both structure and function in the retina, demonstrating not just neuroprotection, but true regenerative capacity-a property rarely seen in ophthalmic drug development.”
This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Terra Innovatum’s SOLO(TM) Micro-Modular Reactor Offers Safe, Affordable, and Reliable 24/7 Power Without Refueling for 15 Years Using Off-the-Shelf Readily Available Commercial Components and Licensed LEU Fuel
NEW YORK CITY, NEW YORK / ACCESS Newswire / May 29, 2025 / Terra Innovatum Srl (“Terra Innovatum,” or the “Company”), a developer of micro-modular nuclear reactors, today announced the submission of its response to the New York State Energy Research and Development Authority’s (“NYSERDA”) Advanced Nuclear Request for Information (“RFI”). The submission outlines plans for selecting a potential test reactor site for the Company’s first-of-a-kind micro-modular reactor, SOLO™, intent to establish a designated production unit, and further commercial deployment opportunities to support the state’s zero-emissions electricity target by 2040. Unlike conventional reactors, the compact footprint, modular design, and ability to operate for 15 years without refueling make SOLO™ well-suited for integration into local energy systems.
In Picture: Rendering of 3 SOLOTM units covering an area of approximately 3,600sqft in a public plaza (totaling 3MWe – 12MWt with Co-Generation).
“We believe SOLO™ represents a pivotal advancement in clean energy infrastructure,” said Alessandro Petruzzi – Co-founder & CEO of Terra Innovatum. “As electricity demand accelerates, driven by AI, data centers, and industrial manufacturing, solutions like SOLO™ will be critical to delivering reliable, zero-carbon power without placing additional strain on the grid. We are excited to showcase the promise of our technology in addressing the urgent energy needs for New York State and look forward to the opportunity to engage with NYSERDA on a potential test reactor site and deployment framework. Importantly, our response to NYSERDA marks the first of many steps toward deploying scalable, plug-and-play energy solutions across the U.S. and beyond. With its low-cost design, 24/7 output, and 15-year fuel cycle, SOLO™ is uniquely positioned to meet the needs of communities, government entities, and businesses seeking energy certainty in an increasingly electrified world.”
In Picture: Rendering of 500 SOLOTM units covering a total of 500 MWe – 2,000 MWt (Co-Generation) energy deployment.
Giordano Morichi – Partner, Chief Business Development Officer & Investor Relations at Terra Innovatum continued: “We see SOLO™ as a transformative and strategic opportunity for New York State to become a national leader in deploying advanced nuclear technologies that enhance energy security, grid resilience, and climate justice. Designed for real-world application, SOLO™ leverages a proven supply chain built entirely on licensed components that have been widely used in the nuclear industry for over 60 years. This approach eliminates the timing and cost risks associated with unlicensed fuels or research-phase technologies with no commercial availability. SOLO™’s inherently safe architecture, scalable deployment model, and cost certainty uniquely positions it to power the State’s industrial hubs, manufacturing sites, ports, transit systems, and data centers, while also revitalizing underserved urban and rural communities. It enables local energy independence, supports sustainable construction, and strengthens resilient infrastructure. In doing so, SOLO™ offers the Empire State a carbon-free, economically competitive energy backbone to meet New York clean energy goals at scale.”
“Safety is our top priority,” affirmed Cesare Frepoli – Co-Founder, COO & Director of Regulatory Affairs at Terra Innovatum. “The compact footprint of SOLO™-approximately 30 ft x 30 ft-combined with its modularity and embedded safeguards, allows for seamless integration in a wide range of environments without the need for expansive emergency planning zones. Its innovative reactor core design is gas cooled by helium, incorporates licensed, off-the-shelf components and utilizes non-proliferant low-enriched uranium (LEU) fuel, which significantly reduces regulatory risk and enhances safety. There is also no water involved in the system, eliminating the risk of hydrogen generation or explosion. Additionally, on top of the various redundancies, the reactor’s inherently low thermal output ensures it operates well below fuel melting thresholds, further reinforcing its passive safety profile,” Dr. Frepoli concluded.
SOLO™ can be deployed across a wide range of environments-including dense urban centers, critical infrastructure corridors, and remote industrial zones-without compromising public security. Its use of non-proliferant, licensed nuclear fuel and embedded safeguards ensures a secure and compliant solution. SOLO™ can be a powerful asset in supporting New York State’s clean energy leadership while simultaneously reinforcing grid resilience, advancing environmental and energy priorities, and driving long-term, sustainable economic growth.
Guided by New York’s Climate Leadership and Community Protection Act, which targets a zero-emissions electricity sector by 2040, NYSERDA’s RFI seeks innovative nuclear solutions to support the state’s energy transformation. Terra Innovatum’s proposal outlines potential deployment scenarios for SOLO™, including site considerations, partners, timeline, and use cases. The Company remains open and eager to engage further with NYSERDA to help advance the role of advanced nuclear energy in New York’s grid.
Recent Highlights
Terra Innovatum recently announced a proposed business combination with GSR III Acquisition Corp., positioning the Company to accelerate its mission of delivering zero-carbon, cost-efficient, and reliable power. SOLO™ is the first micro-modular reactor designed for operation on widely available Low-Enriched Uranium (LEU) and is built using commercial off-the-shelf components, enabling a simplified regulatory pathway and reduced construction timelines. Earlier this year, Terra Innovatum submitted its regulatory engagement plan to the U.S. Nuclear Regulatory Commission (NRC), a critical step toward its targeted first commercial deployment in 2028.
ABOUT NEW YORK STATE ENERGY RESEARCH AND DEVELOPMENT AUTHORITY (NYSERDA)
NYSERDA offers objective information and analysis, innovative programs, technical expertise, and support to help New Yorkers increase energy efficiency, save money, use renewable energy, and reduce reliance on fossil fuels. A public benefit corporation, NYSERDA has been advancing energy solutions and working to protect the environment since 1975.
ABOUT TERRA INNOVATUM & SOLOTM
Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.
It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.
SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.
In connection with the business combination, a Dutch public limited liability company (“Pubco”), GSR III Acquisition Corp. (“GSRT”) and Terra Innovatum s.r.l. (“Terra Innovatum” and, together with GSRT and Pubco, the “Registrant Parties”) have filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus of Pubco relating to the offer of securities to be issued in connection with the business combination, and a preliminary proxy statement of GSRT to be distributed to holders of GSRT’s ordinary shares in connection with GSRT’s solicitation of proxies for a vote by GSRT’s shareholders with respect to the Business Combination and other matters described in the Registration Statement. The Registrant Parties also plan to file other documents with the SEC regarding the business combination. After the Registration Statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to the shareholders of GSRT. INVESTORS OF THE REGISTRANT PARTIES ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS RELATING TO THE BUSINESS COMBINATION THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.
Investors will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about the Registrant Parties once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. In addition, the documents filed by GSRT may be obtained free of charge by written request to GSRT at 5900 Balcones Drive, Suite 100, Austin TX 78731.
PARTICIPANTS IN THE SOLICITATION
Each of the Registrant Parties, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of GSRT is set forth in GSRT’s filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their direct and indirect interests will be set forth in the Registration Statement (and will be included in the proxy statement/prospectus) and other relevant documents when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.
FORWARD LOOKING STATEMENTS
The statements contained in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on GSRT and the other Registrant Parties. There can be no assurance that future developments affecting GSRT and the other Registrant Parties will be those that we have anticipated. These forward-looking statements speak only as of the date this press release is delivered and involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against GSRT, any of the Registrant Parties, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of GSRT or the SEC’s declaration of the effectiveness of the Registration Statement (which will include the proxy statement/prospectus contained therein) to be filed by the Registrant Parties or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability of Pubco to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Terra Innovatum as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination, including the reorganization described in the business combination agreement; (9) changes in applicable laws or regulations; (10) the possibility that the Registrant Parties or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the amount of redemption requests made by GSRT shareholders and (12) other risk factors described herein as well as the risk factors and uncertainties described in the Form S-4 and GSRT’s other filings with the SEC, as well as any further risks and uncertainties to be contained in the proxy statement/prospectus filed after the date hereof. In addition, there may be additional risks that neither GSRT nor any of the other Registrant Parties presently know, or that GSRT or the other Registrant Parties currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward- looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.
None of GSRT, the other Registrant Parties, or any of their respective affiliates, officers, employees or agents, makes any representation or warranty, either express or implied, in relation to the fairness, reasonableness, adequacy, accuracy, completeness or reliability of the information, statements or opinions, whichever their source, contained in this press release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. GSRT, the other Registrant Parties and their respective affiliates, officers, employees and agents further expressly disclaim any and all liability relating to or resulting from the use of this press release and any errors therein or omissions therefrom. Further, the information contained herein is preliminary, is provided for discussion purposes only, is only a summary of key information, is not complete and is subject to change without notice.
In addition, the information contained in this press release is provided as of the date hereof and may change, and neither GSRT nor the other Registrant Parties undertakes any obligation to update or revise any forward- looking statements, whether as a result of new information, inaccuracies, future events or otherwise, except as may be required under applicable securities laws.
STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 2, 2025, and Applied DNA common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (the “Nasdaq”) as of the commencement of market open that same day.
Applied DNA common stock will continue to trade on The Nasdaq Capital Market under the symbol “APDN” following the reverse stock split, with a new CUSIP number of 03815U607. The CUSIP number for the Company’s book entry warrants will not change.
After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced from approximately 7.8 million (as of the date of this press release) to approximately 519 thousand. The total authorized number of shares will not be reduced. Proportional adjustments will be made to the number of shares of common stock issuable upon exercise or vesting of the Company’s outstanding stock options, restricted stock units, and warrants, as well as the applicable exercise or conversion prices, and to the number of shares issuable under the Company’s equity incentive plans and other existing agreements. No fractional shares will be issued in connection with the reverse stock split, and fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share. There will be no change in the par value of $0.001 per share of the common stock as a result of the reverse stock split.
As previously disclosed, at an annual meeting of stockholders held on May 22, 2025, the Company’s stockholders voted to approve a proposal granting the Company’s Board of Directors the discretion to amend the Company’s certificate of incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range from one-for-five to one-for-fifty. The Company’s Board of Directors approved a 1-for-15 reverse stock split on May 27, 2025. The reverse stock split is primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining its listing on Nasdaq. There is no guarantee that the Company will meet the minimum bid price requirement, and even if it does, there is no guarantee that it will be able to meet all additional requirements for continued listing on Nasdaq.
Applied DNA’s transfer agent, Equiniti Trust Company, will provide information to stockholders regarding their stock ownership following the reverse stock split. Stockholders holding their shares in book-entry form or through a bank, broker, or other nominee do not need to take any action in connection with the reverse stock split. Their accounts will be automatically adjusted to reflect the number of shares owned. Beneficial holders are encouraged to contact their bank, broker, or other nominee with any procedural questions.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (“DNA”). Using the polymerase chain reaction (“PCR”) to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase (“RNAP”) for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services.
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company’s expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding the effective date of the reverse stock split and the trading of the common stock on a split-adjusted basis, the Company’s ability to timely implement the reverse stock split, the Company’s belief that the reverse stock split will allow the Company to regain compliance with Nasdaq listing standards, its goal to position the company for long term-growth and value creation, and the potential to achieve that goal, and regarding the future success of its LineaDNA™ and LineaIVT™ platforms. Actual results could differ materially from those projected due to the Company’s history of net losses, limited financial resources, substantial doubt regarding its ability to continue as a going concern, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our LineaDNA and/or LineaIVT platforms, the fact that there has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or LineaIVT platforms, the unknown amount of revenues and profits that will result from its clinical laboratory testing services, as well as various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Reports on Form 10-Q filed on February 13, 2025, and May 15, 2025, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
This collaboration will help replenish groundwater in key river basins in North and South Carolina by providing farmers with cutting-edge technology to improve irrigation efficiency.
SAN FRANCISCO, CA / ACCESS Newswire / May 29, 2025 / Google and Arable are expanding their collaboration in water replenishment efforts by bringing Arable’s in-field irrigation technology to hundreds of fields across North and South Carolina. The project will support the Edisto-Santee River Basin in South Carolina and the Catawba and Pee Dee Basins in North Carolina. This initiative aims to help farmers make precise irrigation decisions using Arable’s crop intelligence platform, while contributing to Google’s goal of replenishing more water than it consumes by 2030.
Google is funding the use of Arable’s technology on 20,000 acres across both states, aiming to save more than 500 million gallons of water annually over an eight-year period. This is expected to have a significant positive impact on groundwater in some of the most at-risk river basins and aquifers in North and South Carolina, aligning environmental goals with farmer profitability and resilience. Scaling irrigation water-use efficiency will deliver multiple benefits to the region, including improved water availability & quality, farmer training on new technology, enhanced on-farm profitability, and reduced greenhouse gas emissions.
“As a soil scientist, I’ve seen firsthand how efficient irrigation protects both our natural resources and our farm productivity,” said Dalton Buchanan, Soil Scientist at the Division of Soil and Water Conservation with the NC Department of Agriculture & Consumer Services. “In North Carolina, smart water use isn’t just good stewardship – it’s essential for long-term agricultural success.”
“Supporting responsible and sustainable water use in agriculture is essential for the long-term health of ecosystems and communities,” said Suzie Shin, Data Center Sustainability Programs Manager at Google. “With data center campuses in both North Carolina and South Carolina, we’re proud to build on our work with Arable to bring this solution to a region we have called home for nearly 20 years.”
Technology That Drives Impact
Arable’s technology and impact have recently been recognized by TIME Magazine, which named it to its 2025 America’s Top GreenTech Companies list, and by Fast Company, which included Arable in its 2025 ranking of the World’s Most Innovative Companies. These honors underscore the company’s role in advancing climate-smart agriculture through actionable, in-field data.
The Arable platform integrates weather, crop, soil, and irrigation data into a single, easy-to-use system, accessible through mobile and web applications. This empowers growers to optimize irrigation decisions based on exactly how much water their crop needs at all times, while improving productivity and operational efficiency.
Results from Arable and Google’s ongoing collaboration in Nebraska and other similar projects have shown that farmers are able to quickly adopt new technology and see real results in reducing groundwater use at scale, while also improving their operations. Approaches such as this that bring together farmers and provide them the tools they need to support and inform their decisions are vital for replenishing groundwater resources across the agricultural system.
“By combining reliable, real-time data with intuitive decision tools, we’re helping farmers do more with less-less water, less energy, and less risk,” said Jim Ethington, CEO at Arable. “We’re excited to bring much needed technology to a region where the need is high and impact to farmers and ecosystems can be significant.”
Looking Ahead
This expanded collaboration marks another step forward in aligning agricultural innovation with environmental stewardship. By combining Google’s commitment to water stewardship with Arable’s advanced crop intelligence technology, the initiative not only supports individual growers but also contributes to the long-term sustainability of the Carolinas’ vital water systems. With training and support built into the program, participating farmers will be equipped to make lasting changes that benefit both their operations and the environment-setting a replicable model for farmer-led, corporate-sponsored water stewardship across the country.
###
About Arable Arable is the leader in climate and water smart agriculture, helping to transform agronomic decision-making through cutting-edge technology. Forward-thinking organizations in over 50 countries rely on Arable to help them be more productive and sustainable.
Arable integrates state-of-the-art IoT technology, machine learning, AI and advanced modeling to convert in-field weather, crop, soil, and irrigation data into real-time, actionable insights. Users are empowered to make informed, proactive decisions that reduce risk and optimize agricultural practices.
Focused on shaping the future of agriculture and water, Arable powers transformative initiatives such as large-scale irrigation optimization that conserve hundreds of millions of gallons of water, and agricultural weather intelligence networks supporting thousands of underserved smallholder farmers around the world.
Consistently recognized for its groundbreaking innovations and impact, Arable is proud to be listed among America’s fastest-growing private companies on the Inc. 5000, ranked #1 in Agtech on TIME’s list of top sustainability-focused companies in agriculture, and featured in Fast Company’s “Most Innovative Companies” list. For more information, visit https://www.arable.com/
TAMPA, FLORIDA / ACCESS Newswire / May 29, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a healthcare infrastructure company transforming the prescription drug ecosystem, today announced its preliminary inclusion in the Russell 2000 and Russell 3000 Indexes, as part of the 2025 Russell US Indexes annual reconstitution. FTSE Russell released the preliminary list of additions and deletions to the Russell 2000 and Russell 3000 Indexes on Friday, May 23, with final inclusion expected to take effect following the close of the U.S. equity market on Friday, June 27, 2025.
The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately 98% of the investable U.S. equity market. The Russell 2000 Index is a subset of the Russell 3000, measuring the performance of the small-cap segment. These indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
“Wellgistics Health’s preliminary inclusion in the Russell 2000 and Russell 3000 indexes marks an important milestone in our company’s journey,” said Brian Norton, CEO of Wellgistics Health. “This recognition enhances our visibility among the broader investment community, supports increased institutional interest and ownership in our stock, and serves as strong validation of our team’s ability to execute on our business plan and drive value to our shareholders.”
About Wellgistics Health
Wellgistics Health, Inc. is a publicly traded healthcare infrastructure company redefining how medications move, are priced, and reach patients. The company operates across pharmaceutical distribution, prescription technology, and clinical fulfillment-connecting over 150 direct manufacturer contracts to a nationwide network of over 6,000 independent pharmacies.
Wellgistics Health provides real-time prescription hub services, compliance-driven logistics, and patient-first fulfillment solutions, while equipping pharmacies with integrated financial, clinical, and digital tools. Its end-to-end platform supports a broad range of therapeutic areas from specialty-lite to chronic maintenance medications by eliminating friction, accelerating reimbursements, and enabling direct, transparent connections between manufacturers, providers, pharmacies, and patients.
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health’s statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans, including without limitation its plan in connection with certain financings and cryptocurrencies and outlook and actions with respect to incurring future expenses. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health’s filings with the SEC, which are available for review at www.sec.gov.
Investor Relations Contact: Skyline Corporate Communications Group, LLC Scott Powell, President 1177 Avenue of the Americas, 5th Floor New York, NY 10036 Office: (646) 893-5835 Email: info@skylineccg.com
INDIANAPOLIS, INDIANA / ACCESS Newswire / May 29, 2025 / Dan O’Toole, CEO of Arrive AI (NASDAQ:ARAI), an autonomous delivery network anchored by patented AI-powered Arrive Points™, is scheduled to take part in a fireside chat at the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow” Presented by Maxim Group LLC on Tuesday, June 3, 2025, at 12 noon EDT.
The rapid evolution of technology is paving the way for disruption across all industries, including healthcare, drones, consumer IoT, business solutions, gaming & entertainment, and more. Maxim’s 2025 Virtual Tech Conference participants will explore how emerging growth companies are expanding their use of Quantum Computing and Artificial Intelligence (AI) to position themselves for the future. Maxim Senior Analysts will facilitate engaging dialogues with CEOs and key management of diverse companies who have their attention on technology and how it will impact and grow their business.
Arrive AI, which made its public debut on the Nasdaq in May, makes autonomous delivery work, ensuring security and chain-of-custody to the intended recipients at the right time. O’Toole’s fireside chat will focus on how Arrive AI is removing friction in the delivery industry with its patented, autonomous delivery network anchored by patented AI-powered Arrive Points™, the various problems it solves, the autonomous delivery ecosystem and regulations that affect it.
The chat will be live on M-Vest. Audience members must register to attend. A video replay will be available shortly afterward. To attend, sign up to become an M-Vest member. Click here to learn more and reserve your seat
-30-
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA SIPC, and NASDAQ. To learn more about Maxim Group, visit maximgrp.com
About Arrive AI
Arrive AI’s patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at www.arriveai.com and see our press kit here.
This news release and statements of Arrive AI’s management in connection with this news release or related events contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements (including statements related to the closing, and the anticipated benefits to the Company, of the private placement described herein) related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would”, “optimistic” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI’s Registration Statement for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
VANCOUVER, BC / ACCESS Newswire / May 29, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec” or the “Company”) is pleased to announce that it has filed its unaudited interim condensed consolidated financial statements and the accompanying management discussion and analysis (“MD&A”) for the three months ended March 31, 2025. The financial statements and MD&A can be accessed under the Company’s SEDAR profile at www.sedarplus.ca .
Julian Treger, CoTec CEO commented; “CoTec had an exceptional start to the year. Our main priority for the quarter was the continued roll-out of HyProMag USA, our Joint Venture U.S. based rare earth elements (“REE”) magnet recycling and permanent magnet manufacturing Project. HyProMag USA selected its preferred bidder for engineering, procurement and construction management (“EPCM”) services, culminating in the engagement of PegasusTSI Inc. (“Pegasus”) and BBA USA Inc. (“BBA”) and the commencement of the detailed design and engineering phase shortly after quarter-end. We have also expanded the scope of the detailed engineering to include three HPMS [i] vessels and initiated concept studies for further expansion and complementary “Long Loop” Recycling.”
“The Project will play a key role in supporting the U.S. strategy of reshoring manufacturing capability, reducing dependence on foreign magnets and rare earths, which is a top priority for the Trump administration. The increased production capacity could also allow the flexibility to produce a wider range of products and specialist magnets, further improving both financial returns and the Project’s ability to become a supplier of choice. HyProMag USA is continuing its ongoing discussions with high-ranking officials in the U.S. Government regarding financial support and project acceleration. The HPMS process remains extremely cost competitive and has independently quantified its exceptionally low CO 2 footprint compared to industry alternatives.
“CoTec secured two new complementary critical mineral technologies targeting the use of Multi-Gravity Technology for the recovery of ultra fine iron and manganese and a joint collaboration with McGill University, Québec, Canada (“McGill”) “WaveCracker TM ” which will investigate extended applications of microwave technologies with the aim of improving low-carbon, economic recovery of valuable metals from a range of mineral targets, with a starting focus on copper recoveries particularly in advanced sulphide leaching application.”
“CoTec believes the significant strategic and commercial value presented by our 60.3 % direct and indirect stake in HyProMag USA combined with the value of our Lac Jeannine project and our other investments, far exceed our current share price. We are encouraged by recent improvements in our share price, but our market valuation still significantly lags the recent uplift in our REE peer group and the disconnect between our share price and the intrinsic value of our assets remains material. We are working hard to address this matter through various investor outreach programs which have been initiated.”
The Company announced a comprehensive loss for the quarter of $1,7 million mainly driven by G&A expenses of $709k and non-cash foreign exchange losses on equity investments and share based compensation of $200k and $269k respectively.
Highlights for the quarter include:
Operational
Invested US$148,500, and US$132,071 into MagIron LLC (“MagIron”) on February 4, 2025, and on March 25, 2025, respectively to maintain its undiluted equity interest
Completed the selection process and commenced negotiations with Pegasus and BBA for their engagement to provide EPCM services for HyProMag USA project with an engagement contract signed on April 20, 2025. Environment and permitting studies will be supported by U.S.-based Weston Solutions, Inc.
Commenced Project WaveCracker TM with McGill University, Québec, targeting the application of microwave technology to accelerate sulphide copper leaching
Entered exclusivity and collaboration agreement with Salter for the use of its multi-gravity technology for the recovery of ultra fine iron and manganese
HyProMag USA expanded detailed design and engineering phase to include three hydrogen processing of magnet scrap (“HPMS”) vessels and initiate concept studies for further expansion, including long loop recycling
HyProMag USA completed independent ISO-Compliant Product Carbon Footprint Study with Minviro Limited (“Minviro”). Minviro confirmed an exceptionally low CO 2 footprint of 2.35 kg CO 2 eq. per kg of NdFeB cut sintered block
Corporate
Executive informational overview report on the Company released by Crystal Research Associates LLC. on February 18, 2025
Drew down $500k on January 6, and February 6, 2025, respectively on the Kings Chapel Convertible Loan Agreement
Agreed an amendment to the Convertible Loan Agreement with Kings Chapel International Limited on February 28, 2025. Pursuant to the amendment, the principal amount available to the Company under the Convertible Loan Agreement was increased by up to $2.5 million. All other terms remain unchanged
Drew down an additional $500 under the Kings Chapel Convertible Loan Agreement on March 5, and March 19, 2025, respectively
Engaged Investing News Network to support an advertising and investor awareness campaign
About CoTec
CoTec is a publicly traded investment issuer listed on the Toronto Venture Stock Exchange (“TSX-V”) and the OTCQB and trades under the symbols CTH and CTHCF respectively. CoTec Holdings Corp. is a forward-thinking resource extraction company committed to revolutionizing the global metals and minerals industry through innovative, environmentally sustainable technologies and strategic asset acquisitions. With a mission to drive the sector toward a low-carbon future, CoTec employs a dual approach: investing in disruptive mineral extraction technologies that enhance efficiency and sustainability while applying these technologies to undervalued mining assets to unlock their full potential. By focusing on recycling, waste mining, and scalable solutions, the Company accelerates the production of critical minerals, shortens development timelines, and reduces environmental impact. CoTec’s strategic model delivers low capital requirements, rapid revenue generation, and high barriers to entry, positioning it as a leading mid-tier disruptor in the commodities sector.
Statements in this press release regarding the Company and its investments which are not historical facts are “forward-looking statements” which involve risks and uncertainties, including statements relating to the roll out of its HyProMag USA and Lac Jeannine projects and its investment in Salter, as well as management’s expectations with respect to other current and potential future investments and the benefits to the Company which may be implied from such statements. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements, due to known and unknown risks and uncertainties affecting the Company, including but not limited to resource and reserve risks; environmental risks and costs; labor costs and shortages; uncertain supply and price fluctuations in materials; increases in energy costs; labor disputes and work stoppages; leasing costs and the availability of equipment; heavy equipment demand and availability; contractor and subcontractor performance issues; worksite safety issues; project delays and cost overruns; extreme weather conditions; and social disruptions. For further details regarding risks and uncertainties facing the Company please refer to “Risk Factors” in the Company’s filing statement dated April 6, 2022, a copy of which may be found under the Company’s SEDAR profile at www.sedar.com. The Company assumes no responsibility to update forward-looking statements in this press release except as required by law. Readers should not place undue reliance on the forward-looking statements and information contained in this news release and are encouraged to read the Company’s continuous disclosure documents which are available on SEDAR at www.sedar.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
